Phase I Trial of RO5126766 Alone and in Combination With Everolimus
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In Part I of the study RO5126766 will be given twice weekly or three times per week in
treatment cycles of 4 weeks to investigate a safe and tolerable dose of the drug.
Once the optimal dosing schedule is defined, the following patients with BRAF, KRAS and/or
NRAS mutations will be enrolled: 26 patients with solid tumours (Part IIA&C), 10 patients
with Multiple Myeloma (Part IIB) and upto 34 patients with solid tumours who will take
RO5126766 in combination with everolimus (Part IID).
Phase:
Phase 1
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
Chugai Pharmaceutical Institute of Cancer Research, United Kingdom